DAFTAR PUSTAKA

Abeler, V.M., Kjørstad, K.E., Berle, E., 1992. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int. J. Gynecol. Cancer 2, 9–22. https://doi.org/10.1046/j.1525-1438.1992.02010009.x

Afify, A.M., Craig, S., Paulino, A.F.G., Stern, R., 2005. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Annals of Diagnostic Pathology 9, 312–318. https://doi.org/10.1016/j.anndiagpath.2005.07.004

Aghajanian, C., Sill, M.W., Darcy, K.M., Greer, B., McMeekin, D.S., Rose, P.G., Rotmensch, J., Barnes, M.N., Hanjani, P., Leslie, K.K., 2011. Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study. JCO 29, 2259–2265. https://doi.org/10.1200/JCO.2010.32.6397

Akhmedkhanov, A., Zeleniuch-Jacquotte, A., Toniolo, P., 2001. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 943, 296–315. https://doi.org/10.1111/j.1749-6632.2001.tb03811.x

Albert, S., Serova, M., Dreyer, C., Sablin, M.-P., Faivre, S., Raymond, E., 2010. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 19, 919–930. https://doi.org/10.1517/13543784.2010.499121

Allegra, A., Alonci, A., Penna, G., Innao, V., Gerace, D., Rotondo, F., Musolino, C., 2014. The Cancer Stem Cell Hypothesis: A Guide to Potential Molecular Targets. Cancer Investigation 32, 470–495. https://doi.org/10.3109/07357907.2014.958231

Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., Vergote, I., 2005. Endometrial cancer. Lancet 366, 491–505. https://doi.org/10.1016/S0140-6736(05)67063-8

Ayhan, Ayse, Tok, E.C., Bildirici, I., Ayhan, Ali, 2001. Overexpression of CD44 Variant 6 in Human Endometrial Cancer and Its Prognostic Significance. Gynecologic Oncology 80, 355–358. https://doi.org/10.1006/gyno.2000.6014

Ayob, A.Z., Ramasamy, T.S., 2018. Cancer stem cells as key drivers of tumour progression. J Biomed Sci 25, 20. https://doi.org/10.1186/s12929-018-0426-4

Bach, P., Abel, T., Hoffmann, C., Gal, Z., Braun, G., Voelker, I., Ball, C.R., Johnston, I.C.D., Lauer, U.M., Herold-Mende, C., Muhlebach, M.D., Glimm, H., Buchholz, C.J., 2013. Specific Elimination of CD133+ Tumor Cells with Targeted Oncolytic Measles Virus. Cancer Research 73, 865–874. https://doi.org/10.1158/0008-5472.CAN-12-2221

Bálint E, E., Vousden, K.H., 2001. Activation and activities of the p53 tumour suppressor protein. Br. J. Cancer 85, 1813–1823. https://doi.org/10.1054/bjoc.2001.2128

Basil, J.B., Goodfellow, P.J., Rader, J.S., Mutch, D.G., Herzog, T.J., 2000. Clinical significance of microsatellite instability in endometrial carcinoma 7.

Beck, B., Blanpain, C., 2013. Unravelling cancer stem cell potential. Nat Rev Cancer 13, 727–738. https://doi.org/10.1038/nrc3597

Binder, P.S., Mutch, D.G., 2014. Update on Prognostic Markers for Endometrial Cancer. Womens Health (Lond Engl) 10, 277–288. https://doi.org/10.2217/WHE.14.13

Braun, M.M., 2016. Diagnosis and Management of Endometrial Cancer. Endometrial Cancer 93, 7.

Cao, G., Savani, R.C., Fehrenbach, M., Lyons, C., Zhang, L., Coukos, G., DeLisser, H.M., 2006. Involvement of Endothelial CD44 during in

Vivo Angiogenesis. The American Journal of Pathology 169, 325–336. https://doi.org/10.2353/ajpath.2006.060206

Carvalho, M.J., Laranjo, M., Abrantes, A.M., Torgal, I., Botelho, M.F., Oliveira, C.F., 2015. Clinical translation for endometrial cancer stem cells hypothesis. Cancer Metastasis Rev 34, 401–416. https://doi.org/10.1007/s10555-015-9574-0

Cheung, L.W.T., Hennessy, B.T., Li, J., Yu, S., Myers, A.P., Djordjevic, B., Lu, Y., Stemke-Hale, K., Dyer, M.D., Zhang, F., Ju, Z., Cantley, L.C., Scherer, S.E., Liang, H., Lu, K.H., Broaddus, R.R., Mills, G.B., 2011. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 1, 170–185. https://doi.org/10.1158/2159-8290.CD-11-0039

Cote, M.L., Ruterbusch, J.J., Olson, S.H., Lu, K., Ali-Fehmi, R., 2015. The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women. Cancer Epidemiology Biomarkers & Prevention 24, 1407–1415. https://doi.org/10.1158/1055-9965.EPI-15-0316

Creasman, W.T., Soper, J.T., McCarty, K.S., McCarty, K.S., Hinshaw, W., Clarke-Pearson, D.L., 1985. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am. J. Obstet. Gynecol. 151, 922–932. https://doi.org/10.1016/0002-9378(85)90671-4

Dossus, L., Allen, N., Kaaks, R., Bakken, K., Lund, E., Tjonneland, A., Olsen, A., Overvad, K., Clavel-Chapelon, F., Fournier, A., Chabbert-Buffet, N., Boeing, H., Schütze, M., Trichopoulou, A., Trichopoulos, D., Lagiou, P., Palli, D., Krogh, V., Tumino, R., Vineis, P., Mattiello, A., Bueno-de-Mesquita, H.B., Onland-Moret, N.C., Peeters, P.H.M., Dumeaux, V., Redondo, M.-L., Duell, E., Sanchez-Cantalejo, E., Arriola, L., Chirlaque, M.-D., Ardanaz, E., Manjer, J., Borgquist, S., Lukanova, A., Lundin, E., Khaw, K.-T., Wareham, N., Key, T.,

Chajes, V., Rinaldi, S., Slimani, N., Mouw, T., Gallo, V., Riboli, E., 2010. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer 127, 442–451. https://doi.org/10.1002/ijc.25050

Dowdy, S.C., Glaser, G.E., Lurain, J.R., 2020. Uterine Cancer, in: Berek & Novak's Gynecology. Wolters Kluwer, Philadelphia, pp. 2141–2201.

Duncan, M., Seagroatt, V., Goldacre, M., 2012. Cancer of the body of the uterus: trends in mortality and incidence in England, 1985-2008: Uterine cancer incidence and mortality. BJOG: An International Journal of Obstetrics & Gynaecology 119, 333–339. https://doi.org/10.1111/j.1471-0528.2011.03201.x

Elbasateeny, S.S., Salem, A.A., Abdelsalam, W.A., Salem, R.A., 2016. Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer. Pathology - Research and Practice 212, 10–16. https://doi.org/10.1016/j.prp.2015.10.008

El-Shorbagy, Safinaz, Oreiby, R., El-Shorbagy, Shahinaz, 2016. Expression of hormone receptors; p53 and CD44 in endometrial carcinoma and their prognostic significance. Life Science Journal 13. https://doi.org/10.7537/marslsj13041610

Felix, A.S., Weissfeld, J.L., Stone, R.A., Bowser, R., Chivukula, M., Edwards, R.P., Linkov, F., 2010. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 21, 1851–1856. https://doi.org/10.1007/s10552-010-9612-8

Fleming, G.F., 2007. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J. Clin. Oncol. 25, 2983–2990. https://doi.org/10.1200/JCO.2007.10.8431

Folkman, J., 1990. What Is the Evidence That Tumors Are Angiogenesis Dependent? JNCI: Journal of the National Cancer Institute 82, 4–7. https://doi.org/10.1093/jnci/82.1.4

Folkman, J., 1971. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186. https://doi.org/10.1056/NEJM197111182852108

Friberg, E., Orsini, N., Mantzoros, C.S., Wolk, A., 2007. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50, 1365–1374. https://doi.org/10.1007/s00125-007-0681-5

Fujita, N., Yaegashi, N., Ide, Y., Sato, S., Nakamura, M., Ishiwata, I., 1994. Expression of CD44 in Normal Human versus Tumor Endometrial Tissues: Possible Implication of Reduced Expression of CD44 in Lymph-Vascular Space Involvement of Cancer Cells' 8.

Giannone, Attademo, Scotto, Genta, Ghisoni, Tuninetti, Aglietta, Pignata, Valabrega, 2019. Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. Cancers 11, 1820. https://doi.org/10.3390/cancers11111820

Globocan, 2018. WHO South-East Asia region (SEARO).

Haldorsen, I.S., Stefansson, I., Grüner, R., Husby, J.A., Magnussen, I.J., Werner, H.M.J., Salvesen, Ø.O., Bjørge, L., Trovik, J., Taxt, T., Akslen, L.A., Salvesen, H.B., 2014. Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. Br J Cancer 110, 107–114. https://doi.org/10.1038/bjc.2013.694

Hayes, M.P., Douglas, W., Ellenson, L.H., 2009. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol. Oncol. 113, 370–373. https://doi.org/10.1016/j.ygyno.2008.12.021

Henley, S.J., Miller, J.W., Dowling, N.F., Benard, V.B., Richardson, L.C., 2018. Uterine Cancer Incidence and Mortality — United States, 1999–2016. MMWR Morb. Mortal. Wkly. Rep. 67, 1333–1338. https://doi.org/10.15585/mmwr.mm6748a1

Hoshimoto, K., Yamauchi, N., Takazawa, Y., Onda, T., Taketani, Y., Fukayama, M., 2003. CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an

independent prognostic marker. Pathol Res Pract 199, 71–77. https://doi.org/10.1078/0344-0338-00357

Hubbard, S.A., Friel, A.M., Kumar, B., Zhang, L., Rueda, B.R., Gargett, C.E., 2009. Evidence for Cancer Stem Cells in Human Endometrial Carcinoma. Cancer Research 69, 8241–8248. https://doi.org/10.1158/0008-5472.CAN-08-4808

Hubbard, S.A., Gargett, C.E., 2010. A cancer stem cell origin for human endometrial carcinoma? REPRODUCTION 140, 23–32. https://doi.org/10.1530/REP-09-0411

Iczkowski, K.A., n.d. Cell adhesion molecule CD44: its functional roles in prostate cancer 7.

Isacke, C.M., Yarwood, H., 2002. The hyaluronan receptor, CD44. The International Journal of Biochemistry 4.

Jayson, G.C., Hicklin, D.J., Ellis, L.M., 2012. Antiangiogenic therapy—evolving view based on clinical trial results. Nat Rev Clin Oncol 9, 297–303. https://doi.org/10.1038/nrclinonc.2012.8

Jenabi, E., Poorolajal, J., 2015. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health 129, 872–880. https://doi.org/10.1016/j.puhe.2015.04.017

Jernigan, A.M., Fader, A.N., 2015. Cancer of the Uterine Corpus, in: The John Hopkins Manual of Gynecology and Obstetrics. Wolters Kluwer, pp. 611–624.

Jia, L., Liu, Y., Yi, X., Miron, A., Crum, C.P., Kong, B., Zheng, W., 2008. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin. Cancer Res. 14, 2263–2269. https://doi.org/10.1158/1078-0432.CCR-07-4837

Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F., Dick, J.E., 2006. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12, 1167–1174. https://doi.org/10.1038/nm1483

Kaufmann, M., Heider, K.H., Sinn, H.P., von Minckwitz, G., Ponta, H., Herrlich, P., 1995. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345, 615–619. https://doi.org/10.1016/s0140-6736(95)90521-9

Konecny, G.E., Santos, L., Winterhoff, B., Hatmal, M., Keeney, G.L., Mariani, A., Jones, M., Neuper, C., Thomas, B., Muderspach, L., Riehle, D., Wang, H.-J., Dowdy, S., Podratz, K.C., Press, M.F., 2009. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br. J. Cancer 100, 89–95. https://doi.org/10.1038/sj.bjc.6604814

Kuhn, S., Koch, M., Nübel, T., Ladwein, M., Antolovic, D., Klingbeil, P., Hildebrand, D., Moldenhauer, G., Langbein, L., Franke, W.W., Weitz, J., Zöller, M., 2007. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 5, 553–567. https://doi.org/10.1158/1541-7786.MCR-06-0384

Leblanc, M., Poncelet, C., Soriano, D., Walker-Combrouze, F., Madelenat, P., Scoazec, J.Y., Darai, E., 2001. Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchows Archiv 438, 78–85. https://doi.org/10.1007/s004280000269

Lee, E.-J., Kim, T.-J., Kim, D.S., Choi, C.H., Lee, J.-W., Lee, J.-H., Bae, D.-S., Kim, B.-G., 2010. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecol. Oncol. 116, 533–538. https://doi.org/10.1016/j.ygyno.2009.11.018

Legras, S., Günthert, U., Stauder, R., Curt, F., Oliferenko, S., Kluin-Nelemans, H.C., Marie, J.P., Proctor, S., Jasmin, C., Smadja-Joffe, F., 1998. A strong expression of CD44-6v correlates with shorter

survival of patients with acute myeloid leukemia. Blood 91, 3401–3413.

Li, Ling, Wang, L., Li, Liang, Wang, Z., Ho, Y., McDonald, T., Holyoake, T.L., Chen, W., Bhatia, R., 2012. Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib. Cancer Cell 21, 266–281. https://doi.org/10.1016/j.ccr.2011.12.020

Lin, J., Ding, D., 2017. The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis. Cancer Cell International 17, 8. https://doi.org/10.1186/s12935-016-0376-4

Lucas, W.E., 2009. The Epidemiology of Endometrial Cancer. GLOWM. https://doi.org/10.3843/GLOWM.10236

Mackay, C., Terpe, H., Stauder, R., Marston, W., Stark, H., Günthert, U., 1994. Expression and modulation of CD44 variant isoforms in humans. Journal of Cell Biology 124, 71–82. https://doi.org/10.1083/jcb.124.1.71

Martincuks, A., Li, P.-C., Zhao, Q., Zhang, C., Li, Y.-J., Yu, H., Rodriguez-Rodriguez, L., 2020. CD44 in Ovarian Cancer Progression and Therapy Resistance—A Critical Role for STAT3. Frontiers in Oncology 10, 2551. https://doi.org/10.3389/fonc.2020.589601

McMeekin, D.S., Gordon, A., Fowler, J., Melemed, A., Buller, R., Burke, T., Bloss, J., Sabbatini, P., 2003. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol. Oncol. 90, 64–69. https://doi.org/10.1016/s0090-8258(03)00203-8

McPherson, C.P., Sellers, T.A., Potter, J.D., Bostick, R.M., Folsom, A.R., 1996. Reproductive factors and risk of endometrial cancer: The Iowa Women's Health study. American Journal of Epidemiology 143, 1195–1202. https://doi.org/10.1093/oxfordjournals.aje.a008707

Miller, D.S., 2016. Endometrial Cancer, in: Williams Gynecology. McGraw-Hill Education, New York, p. 702.

Morrison, C., Zanagnolo, V., Ramirez, N., Cohn, D.E., Kelbick, N., Copeland, L., Maxwell, G.L., Maxwell, L.G., Fowler, J.M., 2006. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J. Clin. Oncol. 24, 2376–2385. https://doi.org/10.1200/JCO.2005.03.4827

Mutter, G.L., 2000. Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers. Journal of the National Cancer Institute 92, 924–930. https://doi.org/10.1093/jnci/92.11.924

Naor, D., Nedvetzki, S., Golan, I., Melnik, L., Faitelson, Y., 2002. CD44 in Cancer. Critical Reviews in Clinical Laboratory Sciences 39, 527–579. https://doi.org/10.1080/10408360290795574

Oda, K., Stokoe, D., Taketani, Y., McCormick, F., 2005. High Frequency of Coexistent Mutations of *PIK3CA* and *PTEN* Genes in Endometrial Carcinoma. Cancer Res 65, 10669–10673. https://doi.org/10.1158/0008-5472.CAN-05-2620

Palmer, D.C., Muir, I.M., Alexander, A.I., Cauchi, M., Bennett, R.C., Quinn, M.A., 1988. The prognostic importance of steroid receptors in endometrial carcinoma. Obstet Gynecol 72, 388–393.

Pavlovic, M., Balint, B., 2015. Bioengineering and Cancer Stem Cell Concept. Springer, New York.

Pecorelli, S., 2009. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105, 103–104. https://doi.org/10.1016/j.ijgo.2009.02.012

Pellerin, G.P., Finan, M.A., 2005. Endometrial cancer in women 45 years of age or younger: A clinicopathological analysis. American Journal of Obstetrics and Gynecology 193, 1640–1644. https://doi.org/10.1016/j.ajog.2005.05.003

Pelupessy, N.U., Andrijono, A., Sutrisna, B., Harahap, A.R., Kanoko, M., Nuranna, L., Siregar, B., Wulandari, D., 2019. CD133, CD44, and ALDH1A1 as cancer stem cell markers and prognostic factors in

epithelial ovarian cancer. Medical Journal of Indonesia 28, 63–9. https://doi.org/10.13181/mji.v28i1.2863

Pokharna, S., 2017. Epidemiology and Prevention of Endometrial Carcinoma, in: Current Concepts in Endometrial Cancer. Springer, Singapore, pp. 19–27.

Pradjatmo, H., Pahlevi, D.P., 2013. Status gizi sebagai faktor prognosis penderita karsinoma endometrium. Jurnal Gizi Klinik Indonesia 10, 10. https://doi.org/10.22146/ijcn.18838

Purdie, D.M., Green, A.C., 2001. Epidemiology of endometrial cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 15, 341–354. https://doi.org/10.1053/beog.2000.0180

Rall, C.J., Rustgi, A.K., 1995. CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res 55, 1831–1835.

Reategui, E.P., de Mayolo, A.A., Das, P.M., Astor, F.C., Singal, R., Hamilton, K.L., Goodwin, W.J., Carraway, K.L., Franzmann, E.J., 2006. Characterization of CD44v3-containing isoforms in head and neck cancer. Cancer Biol Ther 5, 1163–1168. https://doi.org/10.4161/cbt.5.9.3065

Rolitsky, C.D., Theil, K.S., McGaughy, V.R., Copeland, L.J., Niemann, T.H., 1999. HER-2/neu amplification and overexpression in endometrial carcinoma. Int. J. Gynecol. Pathol. 18, 138–143. https://doi.org/10.1097/00004347-199904000-00007

Rose, P.G., Brunetto, V.L., VanLe, L., Bell, J., Walker, J.L., Lee, R.B., 2000. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 78, 212–216. https://doi.org/10.1006/gyno.2000.5865

Rudzki, Z., Jothy, S., 1997. CD44 and the adhesion of neoplastic cells. Mol Pathol 50, 57–71.

Salazar-Martinez, E., Lazcano-Ponce, E.C., Gonzalez Lira-Lira, G., Escudero-De los Rios, P., Salmeron-Castro, J., Hernandez-Avila, M.,

1999. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res 59, 3658–3662.

Santin, A.D., Bellone, S., Gokden, M., Palmieri, M., Dunn, D., Agha, J., Roman, J.J., Hutchins, L., Pecorelli, S., O'Brien, T., Cannon, M.J., Parham, G.P., 2002. Overexpression of HER-2/Neu in Uterine Serous Papillary Cancer 10.

Savani, R.C., Cao, G., Pooler, P.M., Zaman, A., Zhou, Z., DeLisser, H.M., 2001. Differential Involvement of the Hyaluronan (HA) Receptors CD44 and Receptor for HA-mediated Motility in Endothelial Cell Function and Angiogenesis. J. Biol. Chem. 276, 36770–36778. https://doi.org/10.1074/jbc.M102273200

Schmeler, K.M., Soliman, P.T., Sun, C.C., Slomovitz, B.M., Gershenson, D.M., Lu, K.H., 2005. Endometrial cancer in young, normal-weight women. Gynecologic Oncology 99, 388–392. https://doi.org/10.1016/j.ygyno.2005.06.029

Sell, S., 2004. Stem cell origin of cancer and differentiation therapy. Critical Reviews in Oncology/Hematology 51, 1–28. https://doi.org/10.1016/j.critrevonc.2004.04.007

Senbanjo, L.T., Chellaiah, M.A., 2017. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. Front. Cell Dev. Biol. 5. https://doi.org/10.3389/fcell.2017.00018

Siegel, R.L., Miller, K.D., Jemal, A., 2019. Cancer statistics, 2019. CA A Cancer J Clin 69, 7–34. https://doi.org/10.3322/caac.21551

Sivridis, E., 2001. Angiogenesis and endometrial cancer. Anticancer Res. 21, 4383–4388.

Slomovitz, B.M., Coleman, R.L., 2012. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin. Cancer Res. 18, 5856–5864. https://doi.org/10.1158/1078-0432.CCR-12-0662

Smith, M., McCartney, A.J., 1985. Occult, high-risk endometrial cancer. Gynecol. Oncol. 22, 154–161. https://doi.org/10.1016/0090-8258(85)90021-6

Sneath, R.J., Mangham, D.C., 1998. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 51, 191–200.

Soliman, P.T., Oh, J.C., Schmeler, K.M., Sun, C.C., Slomovitz, B.M., Gershenson, D.M., Burke, T.W., Lu, K.H., 2005. Risk Factors for Young Premenopausal Women With Endometrial Cancer: Obstetrics & Gynecology 105, 575–580. https://doi.org/10.1097/01.AOG.0000154151.14516.f7

Sorosky, J.I., 2012. Endometrial Cancer: Obstetrics & Gynecology 120, 383–397. https://doi.org/10.1097/AOG.0b013e3182605bf1

Tang, D., 2012. Understanding cancer stem cell heterogeneity and plasticty. Cell research 22.

Tashiro, H., Isacson, C., Levine, R., Kurman, R.J., Cho, K.R., Hedrick, L., 1997. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 150, 177–185.

Thapa, R., Wilson, G.D., 2016. The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer. Stem Cells International 2016, 1–15. https://doi.org/10.1155/2016/2087204

Thigpen, J.T., Brady, M.F., Alvarez, R.D., Adelson, M.D., Homesley, H.D., Manetta, A., Soper, J.T., Given, F.T., 1999. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J. Clin. Oncol. 17, 1736–1744. https://doi.org/10.1200/JCO.1999.17.6.1736

Torres, A., Pac-Sosińska, M., Wiktor, K., Paszkowski, T., Maciejewski, R., Torres, K., 2019. CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis. BMC Cancer 19, 401. https://doi.org/10.1186/s12885-019-5556-x

TRoCHoN, V., DELPEcH, B., Lu, H., n.d. Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro 5.

Uharček, P., 2008. Prognostic factors in endometrial carcinoma. Journal of Obstetrics and Gynaecology Research 34, 776–783. https://doi.org/10.1111/j.1447-0756.2008.00796.x

Visus, C., Wang, Y., Lozano-Leon, A., Ferris, R.L., Silver, S., Szczepanski, M.J., Brand, R.E., Ferrone, C.R., Whiteside, T.L., Ferrone, S., DeLeo, A.B., Wang, X., 2011. Targeting ALDHbright Human Carcinoma-Initiating Cells with ALDH1A1-Specific CD8+ T Cells. Clinical Cancer Research 17, 6174–6184. https://doi.org/10.1158/1078-0432.CCR-11-1111

Visvader, J.E., Lindeman, G.J., 2008. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8, 755–768. https://doi.org/10.1038/nrc2499

Vivanco, I., Sawyers, C.L., 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489–501. https://doi.org/10.1038/nrc839

Vousden, K.H., Lu, X., 2002. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594–604. https://doi.org/10.1038/nrc864

Wartko, P., Sherman, M.E., Yang, H.P., Felix, A.S., Brinton, L.A., Trabert, B., 2013. Recent changes in endometrial cancer trends among menopausal-age US women. Cancer Epidemiology 37, 374–377. https://doi.org/10.1016/j.canep.2013.03.008

Weigelt, B., Banerjee, S., 2012. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol 24, 554–563. https://doi.org/10.1097/CCO.0b013e328354e585

Wojciechowski, M., Krawczyk, T., Śmigielski, J., Malinowski, A., 2015. CD44 expression in curettage and postoperative specimens of endometrial cancer. Arch. Gynecol. Obstet. 291, 383–390. https://doi.org/10.1007/s00404-014-3407-1

Wu, Y., Sun, W., Liu, H., Zhang, D., 2019. Age at Menopause and Risk of Developing Endometrial Cancer: A Meta-Analysis. BioMed Research International 2019, 1–13. https://doi.org/10.1155/2019/8584130

Xu, W.-H., Xiang, Y.-B., Ruan, Z.-X., Zheng, W., Cheng, J.-R., Dai, Q., Gao, Y.-T., Shu, X.-O., 2004. Menstrual and reproductive factors and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai. Int J Cancer 108, 613–619. https://doi.org/10.1002/ijc.11598

Yorishima, T., Nagai, N., Ohama, K., 1997. Expression of CD44 alternative splicing variants in primary and lymph node metastatic lesions of gynecological cancer. Hiroshima J Med Sci 46, 21–29.

Zhang, X., Kyo, S., Nakamura, M., Mizumoto, Y., Maida, Y., Bono, Y., Takakura, M., Fujiwara, H., 2014. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells. Cancer Letters 345, 106–114. https://doi.org/10.1016/j.canlet.2013.11.020

Zhu, X., Kwon, C.H., Schlosshauer, P.W., Ellenson, L.H., Baker, S.J., 2001. PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res. 61, 4569–4575.

Lampiran 1

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK
Nomor : 603/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 29 September 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20090527		No Sponsor Protokol	
Peneliti Utama	**dr. Gina Magda Riana**		Sponsor	
Judul Peneliti	Hubungan Ekspresi CD44 dengan Faktor Klinikopatologis Kanker Endometrium			
No Versi Protokol	**1**		Tanggal Versi	**28 September 2020**
No Versi PSP			Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin dan RSUP Dr.Wahidin Sudirohusodo Makassar			
Jenis Review	[X] Exempted [ ] Expedited [ ] Fullboard Tanggal		Masa Berlaku **29 September 2020** sampai **29 September 2021**	Frekuensi review lanjutan
Ketua KEPK FKUH RSUH dan RSWS	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**		Tanda tangan	
Sekretaris KEPK FKUH RSUH dan RSWS	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**		Tanda tangan	

Kewajiban Peneliti Utama:
- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2

No	Nama	Stadium	Tipe	Derajat	Invasi	LVSI	Skor-H	Usia	Usia Menopause	IMT	Paritas	Hipertensi	DM
1	Sulistiati Bahtiar	1B	Endometrioid	Grade 3	>50%	Negatif	210	46	Belum	25	Nona	Ya	Tidak
2	Martati	1A	Endometrioid	Grade 1	<50%	Negatif	10	55	51	19,1	P4A0	Tidak	Tidak
3	Halija	1A	Endometriod	Grade 1	<50%	Positif	60	41	Belum	30,6	P1A0	Tidak	Tidak
4	Muderang	1B	Endometriod	Grade 3	>50%	Negatif	150	54	49	17,6	P0A0	Tidak	Ya
5	Sitti Aminah	1A	Endometrioid	Grade 1	<50%	Negatif	70	59	46	25,4	Nona	Ya	Tidak
6	Fransiska Nona Helda	1A	Endometriod	Grade 1	<50%	Negatif	10	57	Belum	26,7	P0A0	Tidak	Tidak
7	Nurlimang	II	Endometriod	Grade 2	>50%	Negatif	5	43	Belum	21,4	Nona	Tidak	Tidak
8	Syamsiah	1B	Endometrioid	Grade 2	>50%	Positif	100	45	51	23,6	P0A0	Tidak	Tidak
9	Ramlah Dg Tarring	II	Endometrioid	Grade 3	<50%	Negatif	70	56	55	21,9	Nona	Tidak	Tidak
10	Hasnawaty	1A	Endometrioid	Grade 1	<50%	Negatif	5	62	Belum	29,4	P1A0	Tidak	Tidak
11	Salmah	1A	Endometrioid	Grade 2	<50%	Negatif	60	40	Belum	26,7	P0A0	Tidak	Tidak
12	Saleha	1A	Endometriod	Grade 1	<50%	Negatif	80	36	Belum	23,5	P4A0	Tidak	Tidak
13	Siniria	IVB	Endometrioid	Grade 1	>50%	Positif	240	52	50	21,4	P6A1	Tidak	Tidak
14	Afniyanty	1A	Endometriod	Grade 1	<50%	Positif	50	60	Belum	30,9	P0A0	Tidak	Tidak

15	Nandang	IIIA	Endometrioid	Grade 1	<50%	Positif	210	41	Belum	28	P1A0	Tidak	Tidak
16	Erni Aris	II	Endometrioid	Grade 3	>50%	Positif	80	52	Belum	20,9	P0A0	Tidak	Tidak
17	Suarni Opusunggu	4B	Endometriod	Grade 2	>50%	Positif	195	53	51	27,8	P3A0	Ya	Tidak
18	Rohati	1A	Papillary Serous	Grade 3	<50%	Negatif	100	33	54	22,1	P0A0	Ya	Tidak
19	Sumarni	1A	endometroid	Grade 1	<50%	Negatif	5	62	Belum	24,2	P2A0	Tidak	Ya
20	Adriani	IVB	endometroid	Grade 2	>50%	Positif	100	62	Belum	27,2	P0A0	Tidak	Tidak
21	Muliyati	1B	Endometrioid	Grade 3	>50%	Positif	180	43	Belum	27,8	P0A0	Ya	Ya
22	Asimah	IVB	Carcinosarcoma (Mixed Mullerian)	Grade 3	>50%	Positif	240	59	49	22,21	P2A0	Tidak	Tidak
23	Arisdawati	IIIC1	Endometrioid	Grade 2	>50%	Positif	50	44	Belum	25,1	P1A2	Tidak	Ya
24	Faujia Hi Ibrahim	IB	Endometrioid	Grade 2	>50%	Positif	100	63	51	24,32	P1A0	Tidak	Tida
25	Hanura	IA	Endometrioid	Grade 2	<50%	Negatif	210	54	50	25,33	P0A5	Tidak	Ya
26	Nura	IA	Adenosquamous cell carcinoma	Grade 2	<50%	Negatif	70	81	52	17,8	P3A0	Tidak	Tidak
27	Suhartini	IIIC1	Adenosquamous cell carcinoma	Grade 2	<50%	Positif	210	53	Belum	29,5	P2A0	Tidak	Tidak
28	Tawiyah	IA	Endometrioid	Grade 2	<50%	Negatif	10	52	Belum	20,5	P0A0	Tidak	Tidak
29	Sitti	IIIC1	Endometrioid	Grade 3	>50%	Negatif	100	59	Belum	29,4	Nona	Tidak	Tidak

30	Agustina	IIIA	Adenosquamous cell carcinoma	Grade 3	>50%	Negatif	210	48	Belum	18,42	P2A0	Tidak	Tidak
31	Nuriyana	IA	Endometrioid	Grade 2	<50%	Negatif	5	46	Belum	29,38	P0A0	Tidak	Tidak
32	Wa Ode Morunga	II	Papilary serous	Grade 2	>50%	Negatif	100	53	50	19,5	P3A0	Tidak	Tidak
33	Sitti Ramlah	IA	Papilary serous	Grade 2	<50%	Negatif	80	52	Belum	25,54	P0A0	Tidak	Tidak
34	Suriani	IA	Endometrioid	Grade 2	<50%	Negatif	100	38	Belum	13,9	P0A2	Tidak	Tidak
35	Suhaemi Anwar	II	Endometrioid	Grade 1	>50%	Negatif	210	69	52	22,8	P7A0	Ya	Tidak
36	Hj Marwah	II	Endometrioid	Grade 2	>50%	Negatif	210	62	50	30,3	P3A0	Ya	Tidak
37	Sitti Rahmawati	IIIA	Endometrioid	Grade 3	>50%	Negatif	210	49	Belum	18,3	P0A1	Tidak	Tidak
38	Nurul Aini Nawawi	II	Endometrioid	Grade 3	<50%	Negatif	120	49	Belum	25,9	P2A0	Tidak	Tidak
39	Lawiah	IA	Endometrioid	Grade 1	<50%	Negatif	60	62	55	30	P2A0	Tidak	Tidak
40	Agustiani Sia	IV B	Endometrioid	Grade 3	<50%	Positif	255	59	53	22,2	P5A0	Tidak	Tidak
41	Nursam	IA	Endometrioid	Grade 3	<50%	Negatif	180	56	51	22,5	P0A0	Tidak	Tidak
42	Renna	IV B	Endometrioid	Grade 2	>50%	Negatif	40	62	55	17,9	P4A0	Ya	Tidak
43	Salimah	II	Endometrioid	Grade 1	>50%	Negatif	80	56	53	21,2	P1A0	Tidak	Tidak

44	Yuliana Usman	IA	Endometrioid	Grade 3	<50%	Negatif	180	54	51	32,9	P1A0	Tidak	Tidak
45	Dian Rozana Boediono	IA	Endometrioid	Grade 3	<50%	Negatif	240	60	52	30,7	P4A1	Tidak	Tidak
46	Mariana	IA	Endometrioid	Grade 2	>50%	Negatif	180	33	Belum	31,6	Nona	Tidak	Ya
47	Saharia Ahmad	IA	Endometrioid	Grade 2	<50%	Negatif	80	48	Belum	24,2	P1A0	Tidak	Tidak
48	Sarah	IA	Endometrioid	Grade 1	<50%	Negatif	10	45	Belum	31,1	P3A1	Ya	Ya
49	Yessy	IIIA	Endometrioid	Grade 2	<50%	Negatif	180	35	Belum	24,3	P0A0	Tidak	Tidak
50	Suryaningsih	IA	Endometrioid	Grade 2	<50	Negatif	70	46	Belum	27,9	P0A0	Tidak	Tidak
51	Hj berlian	IB	Endometrioid	Grade 2	>50%	Negatif	80	49	Belum	33,6	P1A0	Tidak	Tidak
52	Rukmawati	IA	Endometrioid	Grade 1	<50%	Negatif	5	41	Belum	24,6	P0A0	Ya	Tidak
53	Maryam	IA	Endometrioid	Grade 2	<50%	Negatif	100	59	51	23,5	P5A0	Ya	Tidak
54	Irma	IA	Endometrioid	Grade 1	<50%	Negatif	100	38	Belum	28	P0A0	Tidak	Tidak
55	Lily Pawiloi	IV B	Endometrioid	Grade 3	>50%	Positif	240	57	55	23,2	P2A0	Ya	Tidak
56	Rambega Dg Sona	II	Endometrioid	Grade 3	>50%	Positif	180	77	52	17,6	P6A0	Tidak	Tidak
57	Hj Sauwarah	IB	Adenosquamous cell carcinoma	Grade 3	>50%	Positif	180	76	50	28,6	P6A1	Ya	Tidak
58	Rosniati	II	Endometrioid	Grade 3	>50%	Positif	225	53	Belum	20,5	P2A0	Tidak	Tidak

59	Hj Nurmaedah	IIIA	Endometrioid	Grade 2	<50%	Negatif	120	51	Belum	29,5	P1A0	Ya	Ya
60	Hasmani	IIIA	Endometrioid	Grade 2	>50%	Positif	240	56	Belum	30,8	P0A0	Tidak	Tidak
61	Ompo	IIIA	Serous	Grade 3	>50%	Positif	210	55	52	26,7	P0A1	Tidak	Tidak
62	Hapsah	IB	Serous	Grade 3	>50%	Negatif	225	57	52	24,1	P0A0	Tidak	Tidak
63	Sakka	IV B	Endometrioid	Grade 2	>50%	Negatif	180	53	Belum	23,5	Nona	Tidak	Tidak
64	Nurlina	IVB	Clear cell	Grade 3	>50%	Positif	240	61	45	24,1	P0A0	Tidak	Tidak